Fierce Biotech January 29, 2024
Decentralized trials provider Science 37 has agreed to be acquired by telehealth and diagnostics company eMed in an all-cash tender offer valued at around $38 million.
Under the terms of the deal, eMed will snap up all outstanding shares of Science 37 for $5.75 apiece, a premium of about 21.3% over the company’s closing share price last Friday, according to a Jan. 29 press release.
The acquisition, which is expected to be completed by the end of the first quarter, is subject to the tender of a majority of Science 37’s outstanding shares and other customary closing conditions. Once completed, Nasdaq-listed Science 37 will become a private company.
“After an extensive review of opportunities available to Science 37, we believe...
Today's Sponsors
Today's Sponsor